Risankizumab is prescribed for:
- Moderate-to-severe plaque psoriasis
- Psoriatic arthritis
- Crohn's disease
- Dermatologic and gastrointestinal autoimmune conditions
Back to Medication Guide
Risankizumab
Generic Name: Risankizumab-rzaa
Brand Names: Skyrizi
Risankizumab is an IL-23 blocker for psoriasis, psoriatic arthritis, and Crohn's disease.
DermatologicRheumatologicGastrointestinalBiologic
What It's Used For
Side Effects
Common side effects:
- Upper respiratory infections
- Headache
- Fatigue
- Injection site reactions
Serious side effects:
- Serious infections (including TB reactivation)
- Hypersensitivity
Additional Information
What is Risankizumab?
Risankizumab selectively blocks IL-23 by binding to its p19 subunit.
Crohn's Disease Approval
One of the first IL-23 inhibitors approved for Crohn's disease, showing efficacy in inducing and maintaining remission.
Excellent Efficacy
Very high rates of skin clearance in psoriasis trials.
Learn more at MedlinePlus.
Related Health Conditions
This medication is commonly used to treat or manage the following conditions:
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Ask Dr. Zimmer
Have questions about Risankizumab? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.